Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

559.90INR
20 Jul 2018
Change (% chg)

Rs14.80 (+2.72%)
Prev Close
Rs545.10
Open
Rs547.95
Day's High
Rs563.00
Day's Low
Rs545.15
Volume
224,100
Avg. Vol
414,192
52-wk High
Rs608.55
52-wk Low
Rs433.15

Select another date:

Tue, Jun 12 2018

India's Sun Pharma says U.S. FDA clears Halol plant

MUMBAI, June 12 India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) cleared its Halol drug plant, which had been under supply restrictions due to quality control failures.

Indian shares end higher; banks, oil firms gain

May 28 Indian shares ended higher for a third session on Monday, as lower crude prices and a firmer rupee lifted sentiment, with financial and oil stocks accounting for much of the gains.

Indian shares gain as crude oil slips; Sun Pharma top gainer

May 28 Indian equities gained for a third straight session on Monday as a sharp drop in crude prices and a recovery in the rupee boosted sentiment, while shares of Sun Pharmaceutical Industries saw their best day in over three years on strong fourth-quarter results.

UPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit

* Plans to reduce "unviable" generics research (Adds managing director comments from conference call)

India's Sun Pharma Industries Q4 profit up 7 pct, beats estimates

May 25 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, posted fourth-quarter net profit way above expectations.

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA

BRIEF-Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)

* CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text - http://bit.ly/2HRX8j1 Further company coverage:

BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility

* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

Select another date: